Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and End-Stage Renal Disease: Lessons Learned

Alexander P Benz^{1

2}, John W Eikelboom¹

Affiliations

¹ Population Health Research Institute, Hamilton Health Sciences and McMaster University, Ontario, Canada (A.P.B., J.W.E.).
² Department of Cardiology, University Medical Center Mainz, Johannes Gutenberg-University, Germany (A.P.B.).

Editorial

Alexander P Benz et al. Circulation. 2022.

. 2022 Dec 6;146(23):1746-1748.

doi: 10.1161/CIRCULATIONAHA.122.061647. Epub 2022 Dec 5.

Alexander P Benz^{1

2}, John W Eikelboom¹

¹ Population Health Research Institute, Hamilton Health Sciences and McMaster University, Ontario, Canada (A.P.B., J.W.E.).
² Department of Cardiology, University Medical Center Mainz, Johannes Gutenberg-University, Germany (A.P.B.).

No abstract available

Keywords: Editorials; apixaban; atrial fibrillation; kidney failure, chronic; randomized controlled trial; warfarin.

Comment on

Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial.
Pokorney SD, Chertow GM, Al-Khalidi HR, Gallup D, Dignacco P, Mussina K, Bansal N, Gadegbeku CA, Garcia DA, Garonzik S, Lopes RD, Mahaffey KW, Matsuda K, Middleton JP, Rymer JA, Sands GH, Thadhani R, Thomas KL, Washam JB, Winkelmayer WC, Granger CB; RENAL-AF Investigators. Pokorney SD, et al. Circulation. 2022 Dec 6;146(23):1735-1745. doi: 10.1161/CIRCULATIONAHA.121.054990. Epub 2022 Nov 6. Circulation. 2022. PMID: 36335914 Clinical Trial.